These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 35820297)

  • 1. Risk of ipsilateral breast tumor recurrence and contralateral breast cancer in patients with and without TP53 variant in a large series of breast cancer patients.
    Guo Y; Wan Q; Ouyang T; Li J; Wang T; Fan Z; Xie Y
    Breast; 2022 Oct; 65():55-60. PubMed ID: 35820297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Survival After Breast-Conserving Therapy vs Mastectomy Among Patients With or Without the BRCA1/2 Variant in a Large Series of Unselected Chinese Patients With Breast Cancer.
    Wan Q; Su L; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    JAMA Netw Open; 2021 Apr; 4(4):e216259. PubMed ID: 33890992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy.
    Vargas C; Kestin L; Go N; Krauss D; Chen P; Goldstein N; Martinez A; Vicini FA
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1514-21. PubMed ID: 16005576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving local control with breast-conserving therapy: a 27-year single-institution experience.
    Cabioglu N; Hunt KK; Buchholz TA; Mirza N; Singletary SE; Kuerer HM; Babiera GV; Ames FC; Sahin AA; Meric-Bernstam F
    Cancer; 2005 Jul; 104(1):20-9. PubMed ID: 15912514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of ipsilateral breast tumor recurrence following breast conservation surgery: a comparative study of re-conservation vs mastectomy.
    Van den Bruele AB; Chen I; Sevilimedu V; Le T; Morrow M; Braunstein LZ; Cody HS
    Breast Cancer Res Treat; 2021 May; 187(1):105-112. PubMed ID: 33433775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second invasive breast cancers in patients treated with breast-conserving therapy.
    Wang J; Tang H; Yin K; Li X; Xie X; Hughes KS
    Eur J Surg Oncol; 2021 Oct; 47(10):2492-2498. PubMed ID: 34134902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of multifocal or multicentric disease on local recurrence and survival in breast cancer patients with or without BRCA1/2 variants.
    Liu X; Wang Y; Cao K; Yao L; Hu L; Sun J; Zhang J; Xu Y; Xie Y
    Breast Cancer Res Treat; 2023 May; 199(1):25-33. PubMed ID: 36930346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of ipsilateral breast tumor recurrence in primary invasive breast cancer following breast-conserving surgery with BRCA1 and BRCA2 mutation in China.
    Cao W; Xie Y; He Y; Li J; Wang T; Fan Z; Fan T; Ouyang T
    Breast Cancer Res Treat; 2019 Jun; 175(3):749-754. PubMed ID: 30895535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy.
    Pierce LJ; Phillips KA; Griffith KA; Buys S; Gaffney DK; Moran MS; Haffty BG; Ben-David M; Kaufman B; Garber JE; Merajver SD; Balmaña J; Meirovitz A; Domchek SM
    Breast Cancer Res Treat; 2010 Jun; 121(2):389-98. PubMed ID: 20411323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Locoregional Treatments and Ipsilateral Breast Cancer Recurrence Rates in BRCA1/2 Mutation Carriers.
    Bernstein-Molho R; Laitman Y; Galper S; Jacobson G; Boursi B; Gal-Yam EN; Kaufman B; Friedman E; Kaidar-Person O
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1332-1340. PubMed ID: 33259931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased Mortality with Repeat Lumpectomy Alone After Ipsilateral Breast Tumor Recurrence.
    Su Y; Guo R; Xue J; Chi Y; Chi W; Wang J; Yang B; Wu J
    Oncologist; 2019 Sep; 24(9):e818-e827. PubMed ID: 30842240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of Contralateral Breast Cancer in Women with Ductal Carcinoma In Situ Associated with Synchronous Ipsilateral Lobular Carcinoma In Situ.
    Miller ME; Muhsen S; Zabor EC; Flynn J; Olcese C; Giri D; Van Zee KJ; Pilewskie M
    Ann Surg Oncol; 2019 Dec; 26(13):4317-4325. PubMed ID: 31552614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends of Contralateral prophylactic mastectomy at the time of ipsilateral breast tumor recurrence.
    ElSherif A; Armanyous S; Gentle CK; Al-Hilli Z; Valente SA
    Am J Surg; 2022 Mar; 223(3):533-537. PubMed ID: 34924172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy.
    Meric F; Mirza NQ; Vlastos G; Buchholz TA; Kuerer HM; Babiera GV; Singletary SE; Ross MI; Ames FC; Feig BW; Krishnamurthy S; Perkins GH; McNeese MD; Strom EA; Valero V; Hunt KK
    Cancer; 2003 Feb; 97(4):926-33. PubMed ID: 12569592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ipsilateral breast tumor recurrence after breast conservation therapy: outcomes of salvage mastectomy vs. salvage breast-conserving surgery and prognostic factors for salvage breast preservation.
    Alpert TE; Kuerer HM; Arthur DW; Lannin DR; Haffty BG
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):845-51. PubMed ID: 16199315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer.
    Pierce LJ; Levin AM; Rebbeck TR; Ben-David MA; Friedman E; Solin LJ; Harris EE; Gaffney DK; Haffty BG; Dawson LA; Narod SA; Olivotto IA; Eisen A; Whelan TJ; Olopade OI; Isaacs C; Merajver SD; Wong JS; Garber JE; Weber BL
    J Clin Oncol; 2006 Jun; 24(16):2437-43. PubMed ID: 16636335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of ipsilateral breast tumor recurrences after breast-conserving treatment based on the classification of true recurrences and new primary tumors.
    Komoike Y; Akiyama F; Iino Y; Ikeda T; Tanaka-Akashi S; Ohsumi S; Kusama M; Sano M; Shin E; Suemasu K; Sonoo H; Taguchi T; Nishi T; Nishimura R; Haga S; Mise K; Kinoshita T; Murakami S; Yoshimoto M; Tsukuma H; Inaji H
    Breast Cancer; 2005; 12(2):104-11. PubMed ID: 15858440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent lobular neoplasia increases the risk of ipsilateral breast cancer recurrence in patients with ductal carcinoma in situ treated with breast-conserving therapy.
    Rudloff U; Brogi E; Brockway JP; Goldberg JI; Cranor M; Wynveen CA; Nehhozina T; Reiner AS; Patil S; Van Zee KJ
    Cancer; 2009 Mar; 115(6):1203-14. PubMed ID: 19170233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contralateral breast cancer and tumor recurrence in BRCA1/2 carriers and non-carriers at a high risk of hereditary breast cancer after bilateral mastectomy.
    Allué Cabañuz M; Domingo Bretón M; Chóliz Ezquerro J; Arribas Del Amo MD; Güemes Sánchez AT
    Cir Esp (Engl Ed); 2020 Dec; 98(10):612-617. PubMed ID: 32505558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of lobular carcinoma in situ in association with invasive breast cancer on the rate of local recurrence in patients with early-stage breast cancer treated with breast-conserving therapy.
    Jolly S; Kestin LL; Goldstein NS; Vicini FA
    Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):365-71. PubMed ID: 16965988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.